News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Breaking Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
Medicus Pharma Ltd. is set to present at Biotech Showcase 2026, highlighting the upcoming readout of its Phase 2 SkinJect clinical data. This presentation underscores the company's strategic focus on advancing select programs through proof-of-concept and pursuing strategic partnerships.
Latest News
FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
The FDA has approved FoundationOne CDx as a companion diagnostic for inavolisib (Itovebi) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. This approval expands the targeted therapy landscape and underscores the importance of genomic testing in patient selection.
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means — drug approvals
HHS Secretary Robert F. Kennedy Jr. announced the FDA will reclassify approximately 14 peptides from Category 2 (restricted) to Category 1 (allowable) for compounding pharmacies. This shift, based on the claim that original restrictions lacked legitimate safety signals, opens new market access for unproven peptides and signals a regulatory pivot with significant implications for pharma BD teams and investors.
Scientists uncover a new hiding spot for HIV in bone marrow: Implications for cure research
A team led by virologist Kathleen Collins at the University of Michigan has discovered that HIV can hide inside bone marrow cells, revealing a previously unknown reservoir. This finding challenges current cure strategies and opens new avenues for therapeutic targeting.
Trump Administration Strips Job Protections of Top NIH Officials: What Pharma Teams Must Know
President Trump issued an executive order stripping civil service protections from approximately 8,000 NIH employees, including senior grants officials. The move makes the grants process more susceptible to political influence and threatens the stability of NIH RePORTER and eRA Commons systems.
Fierce Biotech Week 2026: Key Insights and Highlights
Fierce Biotech Week 2026 delivered critical updates on gene therapy, mRNA platforms, and regulatory shifts from the FDA and EMA. This article provides key takeaways, implications for BD teams and investors, and a FAQ section.
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
The FDA approved AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) as a first-line treatment for triple-negative breast cancer on May 1, 2026. This article provides key takeaways, regulatory details, and strategic implications for pharma decision-makers.
Pharma in Focus: Regulatory Updates You Need to Know
The pharmaceutical industry faces sweeping regulatory changes that reshape drug approval timelines and increase scrutiny on clinical trial data. This article covers key takeaways from the June 2026 Temple University event and their implications for BD teams, investors, and analysts.
FDA Flashback: Key Breast Cancer Decisions from April 2026
April 2026 brought pivotal FDA actions in breast cancer, including an ODAC split vote on AstraZeneca's candidate and a breakthrough device designation. This article analyzes the decisions, their competitive impact, and what pharma teams should watch next.
FDA Approves First Oral COVID-19 PEP Drug, Xocova
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute
Highmark Health has filed a lawsuit against HaloMD, alleging the No Surprises Act middleman used a 'sham letter' and misleading data to extract inflated payments. This is the fourth such lawsuit from an insurer, highlighting growing tensions over arbitration abuse.
STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
Structured plan for STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
The Military's Role in the Rising Tide of Eating Disorders
Military service members and veterans exhibit higher rates of eating disorders compared to the general population, a trend linked to specific psychological and environmental factors within the armed forces. These conditions carry significant mortality risks and have implications for veteran healthcare and disability.
FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives
The FDA has released a blueprint to reduce regulatory risks associated with alternatives to animal testing, signaling a significant shift in drug development and regulatory pathways. This initiative aims to streamline the adoption of new approach methodologies (NAMs), potentially accelerating drug approvals and influencing investment strategies.
China’s Rise in Drug Development Looms Over U.S. Oncology Market
Structured plan for China’s Rise in Drug Development Looms Over U.S. Oncology Market
FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors
The FDA's decision not to issue specific guidance on foreign drug imports leaves the pharmaceutical industry navigating a complex regulatory landscape. This update impacts market strategies, compliance, and investment considerations.
Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights
Q2 2026 is poised to be a pivotal quarter for the ophthalmology pipeline, with several key clinical trial readouts and potential regulatory decisions on the horizon. These milestones will significantly influence market dynamics and strategic investment for pharmaceutical companies.
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact
Real-world data (RWD) from Electronic Health Records (EHRs) and claims offers significant value for pharmaceutical research and regulatory submissions. However, understanding its inherent strengths and limitations is crucial for effective utilization.
The Common Fund Data Ecosystem (CFDE)
Structured plan for The Common Fund Data Ecosystem (CFDE)